DOCU Stock Price and Chart NASDAQ:DOCU

The yield on the 10-year Treasury rose to 3.57% from 3.54% late Tuesday. Banks are struggling with high interest rates, which have caused some customers to pull their deposits in search of higher yields at money-market funds and other accounts. The charge higher in interest rates over the last year has also knocked down the values of many of the loans and bonds that banks own. Stocks of companies that get much of their revenue from the federal government, and thus may have much to lose if it can’t pay its bills, were ticking a bit higher.

Target offered some potentially encouraging data on the strength of shoppers when it said its profit fell by less last quarter than analysts feared. But it also said that it’s seeing softening sales trends early this year, and it did not raise its forecast for full-year earnings. You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. Regional-bank shares are jumping after Western Alliance—a lender investors have worried about—gave a positive update on deposit growth.

The firm now rates Wynn Resorts stock as overweight with 31% upside compared to current trading levels. Barclays also highlighted the company’s performance in its Las Vegas properties. Semiconductor stocks shined as another bright spot, with shares of Nvidia last up 2.7%. Advanced Micro Devices jumped 2.2%, while ON Semiconductor and Applied Materials popped more than 4% each.

The headline numbers for DocuSign (DOCU) give insight into how the company performed in the quarter ended January 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estim… DocuSign’s (DOCU) uptick in subscription revenue enables it to provide year-over-year revenue growth. Recently, Zacks.com users have been paying close attention to DocuSign (DOCU). Work-from-home stocks have weathered a rollercoaster ride as the pandemic-led tailwinds faded away. These stocks flourished because of the rapid shift to remote work, but faced turbulence, as did the … The anywhere economy is estimated to add $19.4 trillion in cumulative GDP and an average of 10% productivity growth in the ten studied countries by 2030 Two-thirds of executives believe remote work an…

This is an imaging biomarker tool which is capable of measuring liver fat content, so that a liver biopsy would not be done at this point. The reason why is because the data that was just released was to measure liver fat content reduction of drug compared to placebo. The primary endpoint of this study was to evaluate the change in liver fat content from baseline to week 12 between VK2809 versus placebo. With respect to the highest dose of 10 mg VK2809, the primary endpoint was achieved with statistical significance in that an average 52% mean relative change in liver fat reduction was achieved.

Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Much scrutiny has been on Western Alliance Bancorp and other smaller and mid-sized banks, which has led to wild swings in their stock prices. Western Alliance recovered some of its losses after it gave an update on its deposit levels through May 12, among other data.

This is going to be a large market opportunity for the biotech, should it eventually get this drug to market for this patient population. It is expected that the global non-alcoholic steatohepatitis market will reach $16.3 billion by 2030. This mid-stage study compared the use of VK2809 versus placebo in this patient population.

I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. I primarily Like to Invest In biotechnology stocks and I accept the risks. As I https://business-oppurtunities.com/3-killer-ways-to-ignite-your-affiliate-commissions/ noted above, Viking Therapeutics released positive results from its phase 2b VOYAGE study, which used VK2809 for the treatment of patients with non-alcoholic steatohepatitis [NASH].

Earnings Transcripts

The comments come a day after President Joe Biden met with top congressional leaders to try to find a way around the debt impasse. McCarthy said the talks resulted in a «structure» to find a solution while noting that the deadline remains «tight» as Republicans look for spending cuts and Democrats seek a clean bill not tied to conditions. «I think at the end of the day we do not have a debt default,» he said on CNBC’s «Squawk Box.» «I think we finally got the president to agree to negotiate.»

Retailers are among the last of big U.S. companies to report their profits for the start of the year. Most companies in the S&P 500 have turned in earnings that were better than analysts feared. But they’re still on pace to finish with a second straight quarter of drops in profit from year-ago levels. A day earlier, Home Depot raised worries when it cut its financial forecasts for the year after highlighting broad-based pressures across its business.

Regional bank stocks are advancing after a positive update from Western Alliance

That’s because it was able to achieve the primary endpoint of liver fat reduction of VK2809 compared to placebo, in the phase 2b VOYAGE study. What remains now is another major catalyst, which is expected in the 1st half of 2024. This is when the biotech will release 52-week biopsy data from this phase 2b VOYAGE study. The 52-week biopsy data, which is a more invasive to measure liver damage, is expected to be released in the 1st half of 2024. A liver biopsy is more invasive than other tests, as it requires a doctor to make a small cut on the neck and then use a needle to make a small hole into the jugular vein.

Of the 11 S&P 500 sectors, only health care, consumer staples and utilities were trading in negative territory during midday trading. EVGo — The EV charging station supplier fell nearly 16% in midday trading on news of a public offering of $125 million Class A stock. Earlier on Tuesday, Stifel initiated coverage of EVGo with a buy rating.

Yahoo Finance Live’s Seana Smith looks out several stocks trending in the after-hours trading session. According to 18 analysts, the average rating for DOCU stock is «Hold.» The 12-month stock price forecast is $65.25, which is an increase of 24.36% from the latest price. The second risk to consider would be with respect to VK2735, which is being developed as a weight loss drug. For starters, there is no guarantee that it will be able to develop an oral formulation of this drug.

Expect more tight trading over the next week, JPMorgan says

Exelon and Sempra led utility stocks down with week-to-date losses larger than 5% each. The technician pointed out market activity on Monday as an example, when the most liquid short rose 3.68%, but then dropped 2.77% on Tuesday. Current board member David Tolley has been named interim CEO, but that did not soothe investors in the penny stock.

Stocks surged to session highs during midday trading as hopes that an agreement will be reached on debt ceiling negotiations grew on Wall Street. The Technology Select Sector SPDR Fund (XLK) rose 1.2%, hitting a 52-week high. It’s the third straight session that the fund reached that milestone. «DocuSign changed the way millions of businesses operate by providing a secure, reliable, and seamless way to manage documents,» said Blake Grayson. «Allan and the rest of the executive team have laid the foundation for growth and have a well-defined strategy in place. I’m looking forward to helping lead the company as it enters its next chapter.»

From there, the doctor inserts a thin flexible tube [catheter] through the veins to the liver. Lastly, a biopsy needle will run through the catheter so that a tissue sample can be taken. As you can see, for the first part of a NASH study, measuring liver fat reduction with MRI-PFF is preferred first. Regardless, a biopsy is going to be done for all patients at 52 weeks to measure liver fibrosis. Its cloud based electronic signature platform helps companies and individuals securely collect information, automate data workflows and sign anything.

Malhotra changed his rating from buy to neutral and said his prior expectations will likely not be met. He said 76% occupancy by the end of this year and 78% by the end of 2024 are likely unachievable, which can lead to higher cash burn and prompt the need for outside capital. He also said the company will likely not be free cash flow positive until its 2025 fiscal year. Sam Stovall, chief investment strategist at CFRA Research, said he expects that markets are stuck in neutral, even as the news becomes «more and more optimistic» on the debt ceiling. He cited recent trends in the 10-year Treasury yield, as well as strength indicators in the S&P 500. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

There are several risks that traders/investors should be aware of before investing in Viking Therapeutics. The first risk to consider would be with respect to the 52-week NASH biopsy data, which is expected to be released in the 1st half of 2024. One approach is that a phase 1 study was initiated using VK2735 for weight loss to find a way to develop a solid oral formulation of this drug.

The 50-day moving average is a short-term technical indicator of where an asset or an index is trading. A close below that level may signal a potential change toward the downside. For the current quarter, the company said to expected between $2 and $2.06 in earnings per share for the current quarter, while analysts forecasted $1.96. Keysight guided revenue for the quarter to come in between $1.37 billion and $1.39 billion, a range that contains Wall Street’s consensus estimate of $1.38 billion. Regional bank shares rebounded on Wednesday, helping market sentiment, as Western Alliance Bancorp detailed improving deposit growth. The SPDR S&P Regional Bank ETF jumped 3.4%, while Western Alliance soared 12%.

The Trade Desk

Data may be intentionally delayed pursuant to supplier requirements. DocuSign (DOCU) closed at $49.30 in the latest trading session, marking a +1.17% move from the prior day. The e-signature company warned of a worsening macroeconomic backdrop, and analysts raised concerns about stepped-up competition.

Hopefully, Viking achieves positive biopsy data, because it will reinforce all other prior liver fat reduction data which it has released to date. There is another catalyst for traders/investors in 2023 to look forward to still. It is stated that the company will release the results from the phase 2b VOYAGE study at an upcoming medical meeting this year. The final conclusion is that Viking Therapeutics, Inc. is a good speculative biotech play to look into.

The two-year yield, which moves more on expectations for action by the Federal Reserve, rose to 4.15% from 4.08%. According to the 10-Q SEC Filing, Viking Therapeutics had $135.7 million in cash, cash equivalents and short-term investments as of March 31, 2023. It believed that it would have enough cash to fund its operations until at least June 30, 2024.

Risks To Business

Barclays upgraded Wynn Resorts stock on Tuesday, and cited the company’s continued performance in Macau as a driver for growth. President Joe Biden made additional remarks on the debt ceiling and budget talks late morning Wednesday from the White House, calling the meeting with House Speaker Kevin McCarthy and other congressional leaders «productive.» The three major averages jumped to their highs of the day – briefly – after President Joe Biden said that the U.S. will not default on its debts Wednesday morning.

• The 52-week biopsy data, which is a more invasive to measure liver damage, is expected to be released in the 1st half of 2024.
• The company expects adjusted EBITDA for the year to come in between $216 million and $222 million, while analysts anticipate $215.7 million.
• The technician pointed out market activity on Monday as an example, when the most liquid short rose 3.68%, but then dropped 2.77% on Tuesday.
• This could act as another catalyst for traders/investors to look forward to.
• Home prices in China fell, with prices 0.2% lower year-on-year, compared to a 0.8% decline seen in the previous month, according to Reuters’ calculations.

DocuSign stock was a pandemic darling, but it’s dealing with a very different business environment today. Some tech investors are hoping that banking troubles will slow the Federal Reserve’s inflation fight. Understanding how revenue comes into a business and turns into profit is imperative for an investor. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Both of those estimates were below consensus expectations, with analysts polled by FactSet anticipating revenue at $11.8 million and adjusted EBITDA at $45.4 million. The pan-European Stoxx 600 index was down 0.2% at the start of the session, with most sectors and major bourses trading in negative territory. Financial services made the biggest losses, down 1.3%, followed by autos, which dropped 0.9%. «While McCarthy said a deal is possible by end of this week, the timeline may be by the end of next week ahead of the Memorial Day,» JPMorgan traders wrote. «With that in mind, Equities may trade in a tight range until an outcome is observed with the biggest downside risk coming if we enter Memorial Day weekend without a solution, given the early June x-date.»